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MaBACKGROUND Patients with colorectal cancer (CRC) often present with dyspnea and fatigue. These are also
frequent symptoms in patients with chronic heart failure (CHF).
OBJECTIVES We hypothesized that similar patterns of cardiovascular perturbations are present in CRC and CHF.
METHODS We prospectively studied 50 patients with CRC, 51 patients with CHF, and 51 control subjects. The CRC
group was divided into 2 subgroups: patients who underwent chemotherapy (n ¼ 26) and chemotherapy-naive patients
(n ¼ 24). We assessed exercise capacity (spiroergometry), cardiac function (echocardiography), heart rate variability
(Holter electrocardiography), body composition (dual-energy x-ray absorptiometry), and blood parameters.
RESULTS Compared with the control arm, the left ventricular ejection fraction (CRC group 59.4%; control group
62.5%) and exercise performance as assessed by peak oxygen consumption (peak VO2) (CRC group 21.8 ml/kg/min;
control group 28.0 ml/kg/min) were signiﬁcantly reduced in CRC patients (both p < 0.02). Markers of heart rate
variability were markedly impaired in CRC patients compared with control subjects (all p < 0.008). Compared with
the control group, the CRC group also showed reduced lean mass in the legs and higher levels of the endothelium-
derived C-terminal-pro-endothelin-1 (both p < 0.02). Major determinants of cardiovascular function were impaired
in chemotherapy-treated patients and in the chemotherapy-naive patients, particularly with regard to exercise capacity,
left ventricular ejection fraction, lean mass, and heart rate variability (all p < 0.05 vs. control subjects).
CONCLUSIONS Some aspects of cardiovascular function are impaired in patients with CRC. More importantly,
our ﬁndings were evident independently of whether patients were undergoing chemotherapy. (J Am Coll Cardiol
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AB BR E V I A T I O N S
AND ACRONYM S
5-FU = 5-ﬂuorouracil
CHF = chronic heart failure
CRC = colorectal cancer
CT-proET = C-terminal
pro-endothelin
FEV1 = forced expiratory
volume in 1 second
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1311optimal health in this group of patients. Although
treatment of some cancer- or therapy-related symp-
toms has improved considerably, there is still no
accepted treatment for complaints of fatigue. The
exact origin of fatigue in cancer patients is unknown;
it may be caused by the disease itself, by its treat-
ment, or it may be a psychological response (2). Fa-
tigue can lead to impaired quality of life, decreased
levels of physical activity (detraining), and increased
incidences of sick leave (3).SEE PAGE 1320
FVC = forced vital capacity
HF = high frequency
HRV = heart rate variability
hsCRP = high-sensitivity
C-reactive protein
hsTnT = high-sensitivity
troponin T
LF = low frequency
LVEDV = left ventricular
end-diastolic volume
LVEF = left ventricular
ejection fraction
LVESV = left ventricular
end-systolic volume
LVM = left ventricular mass
MR-proADM = mid-regional
pro-adrenomedulin
MR-proANP = mid-regional
pro-atrial natriuretic peptide
SDANN = SD of 5-min mean RR
intervals
SDNN = SD of all normal RR
intervals
SDNN index = mean of the SD
of normal RR intervals every
5 min
VCO2/VO2 = respiratory
exchange ratio
VE/VCO2 = ratio of minute
ventilation and carbon dioxide
output
VLF = very low frequency
VO2 = oxygen consumptionUnderstanding the pathophysiology of fatigue may
help to develop therapies aimed at improving pa-
tients’ exercise capacity, and thus, quality of life.
Because fatigue is also a frequent observation in pa-
tients with chronic heart failure (CHF), comparing
CRC and CHF may be clinically worthwhile. Both
groups of patients with CRC and CHF present with
similar symptoms, such as impaired exercise capacity,
dyspnea, or weight loss. Recent data have shown that
CHF, once considered a pure hemodynamic problem,
is a complex interplay of underlying cardiac injury,
chronic neurohormonal stress, immune activation,
and metabolic imbalance (4).
We hypothesized that aspects of the well-known
pathophysiology of CHF play an important role in
understanding the impairment of exercise capacity in
patients with CRC, independent of the commence-
ment of chemotherapy. To better understand these
mechanisms, we studied body composition, cardiac
function, exercise capacity, heart rate variability
(HRV), and blood parameters in patients with CRC
and compared these with the parameters in control
subjects and in patients with CHF.
METHODS
PATIENT RECRUITMENT. We prospectively studied 50
patients with CRC, 51 patients with CHF, and 51 control
subjects of similar age. Table 1 lists the patients’ clinical
characteristics. We recruited CRC patients from the
Department of Hematology and Oncology of the Charité
Medical School, Campus Virchow-Klinikum, Berlin, Ger-
many, between July 2009 and November 2010. We identi-
ﬁed and screened patients with CRC for eligibility by
medical chart review of patients scheduled to attend treat-
ment or in treatment of CRC. The primary diagnosis of CRC
was on the basis of histological proof from tissue biopsy.
Exclusioncriteria forpatientswithCRCwereclinical signsof
infection, inﬂammatory disease, chronic obstructive pul-
monary disease, clinical signs or symptoms of CHF, signif-
icant cardiovascular disease other than hypertension, other
cancer diagnosis in the 5 years before recruitment, age <18years, andanEasternCooperativeOncologyGroup
performance status of more than 2. Patients with
CHF of similar age to patients with CRC were
included when the following criteria were met:
symptoms and clinical signs of CHF and docu-
mented left ventricular impairment measured by
echocardiography (left ventricular ejection frac-
tion [LVEF] #45%). All patients were stable and
weremaintainedon theirmedications for at least 4
weeks before being studied. Control subjects of
similar age were recruited from patients’ relatives
and hospital staff. They were allowed
antihypertensive or antidiabetic medication.
Table 2 lists the subjects’ medications. All cancer
patients completed the questionnaire Short Form-
36 about their quality of life.
To understand the impact of chemotherapy
in the course of CRC, the CRC group was
divided into 2 subgroups: the ﬁrst group
included patients who were already being
treated (26 patients), and the second group
included patients who were just diagnosed
with CRC and were not receiving therapy
(24 patients). The local ethics committee
approved the study, and all subjects provided
written informed consent.
BLOOD COLLECTION. Venous blood was
collected from an antecubital vein and
analyzed immediately. Full blood count, clin-
ical chemistry parameters, and coagulation
were analyzed according to local labo-
ratory standard operating procedures. High-
sensitivity C-reactive protein (hsCRP) was
assessed using particle-enhanced nephelom-
etry BN2 (Siemens Healthcare Diagnostics
GmbH, Eschborn, Germany); the lower
reference limit was 5 mg/l. Levels of high-
sensitivity troponin T (hsTnT) were mea-
sured by electrochemiluminescence on a
Cobas 8000 analyzer (Roche Diagnostics,
Mannheim, Germany); the lower reference
limit was 14 pg/ml. After centrifugation, aliquots were
stored at –80C before analysis.Detection of mid-
regional pro-adrenomedulin (MR-proADM), C-termi-
nal pro-endothelin (CT-proET)-1, mid-regional
pro-atrial natriuretic peptide (MR-proANP), and the
C-terminal portion of pro-vasopressin, copeptin, was
performed using novel assays provided by Thermo
Fisher/B.R.A.H.M.S GmbH (Hennigsdorf, Germany).
The analytical detection limits of these assays are
0.08 nmol/l (5), 0.4 pmol/l (6), 20 pmol/l (7), and 1.7
pmol/l (8), respectively. Due to the lack of material,
hsCRP was not measured in control subjects, MR-
proADM and MR-proANP were not measured in 8
TABLE 1 Clinical Characteristics of Control Subjects, Patients With CRC,
and Patients With CHF
Control
Subjects
(n ¼ 51)
Patients
With CRC
(n ¼ 50)
Patients
With CHF
(n ¼ 51) p Value*
Age, yrs 61.3  11.2 59.9  12.0 63.5  10.9 0.26
Male 50.9 40.0† 82.3‡ < 0.001
Body mass index, kg/m2 24.9  3.3 25.5  5.2§ 27.5  5.0k 0.02
Heart rate, min1 64.7  12.3 73.0  10.9†‡ 64.6  11.2 0.0002
Systolic blood pressure,
mm Hg
128.9  17.7 126.1  17.7 118.9  23.0¶ 0.03
Diastolic blood pressure,
mm Hg
78.8  10.2 76.9  8.5§ 72.5  11.5k 0.007
Hemoglobin, g/dl 14.1  1.1 12.0  1.3†‡ 13.4  1.5k < 0.001
Leukocytes, nl1 6.3  1.7 6.0  1.9# 7.2  2.4¶ 0.006
Platelets, nl1 234.8  57.2 266.0  86.6§ 230.7  80.2 0.09
Sodium, mmol/l 141.6  2.2 140.5  2.8 141.1  3.8 0.17
Potassium, mmol/l 4.2  0.4 4.0  0.3# 4.3  0.5 0.02
Creatinine, mg/dl 0.9  0.1 0.8  0.2† 1.1  0.3‡ < 0.001
ALT, U/l 25.3  13.1 30.0  39.5 24.9  12.7 0.85
AST, U/l 25.0 (22.0–29.0) 23.0 (20.0–32.0) 26.0 (22.2–33) 0.81
GGT, U/l 25.0 (17.0–30.0) 42.0 (25.0–82.0)‡ 43.0 (31.5–67.7)‡ < 0.001
Albumin, g/l 40.3  5.5 36.4  4.4‡ 36.7  3.9‡ 0.0002
Values are mean  SD, %, or odds ratio (95% conﬁdence intervals). *Analysis of variance or chi-square p value.
†p<0.001 versus patients with CHF. ‡p<0.001 versus control subjects. §p<0.05 versus patients with CHF.
kp<0.01 versus control subjects. ¶p<0.05 versus control subjects. #p<0.01 versus patients with CHF.
ALT ¼ alanine aminotransferase; AST ¼ aspartate aminotransferase; CHF ¼ chronic heart failure;
CRC ¼ colorectal cancer; GGT ¼ gamma-glutamyl transferase.
TABLE 2
Aspirin
ACE-I/ARB
Beta-bloc
Spironolac
Diuretics
Anticoagu
Lipid-lowe
Antidiabet
Insulin
Proton pu
Opioids
Antidepre
Values are %
ACE-I ¼ a
abbreviation
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1312control subjects and 3 CHF patients, and CT-proET-1
and copeptin were not measured in the CHF group
and 19 control subjects.
CARDIOVASCULAR ASSESSMENTS AND BODY
COMPOSITION. All subjects underwent transthoracic
2-dimensional echocardiography using a Vivid S6
ultrasonographic system (GE Healthcare, Waukesha,
Wisconsin). LVEF, left ventricular end-systolic vol-
ume (LVEDV), and left ventricular end-diastolicMedication at Study Entry
Control Subjects
(n ¼ 51)
Patients With CRC
(n ¼ 50)
Patients With CHF
(n ¼ 51)
8 8 78
12 24 96
ker 6 12 94
tone 0 4 57
6 10 75
lants 0 2 43
ring drugs 12 8 29
ics 2 6 8
0 4 16
mp inhibitors 0 32 31
0 8 2
ssants 0 8 10
.
ngiotensin-converting enzyme inhibitor; ARB ¼ angiotensin-receptor blocker; other
s as in Table 1.volume (LVESV) were calculated using multiplane
techniques. If multiplane assessment was impossible,
measurements were obtained from monoplane views
(<20% of patients). The LVEDV index and the LVESV
index were assessed as LVEDV or LVESV divided by
body surface area. Left ventricular mass (LVM) was
calculated following the recommendations of the
American Society of Echocardiography (9). The LVM
index was obtained as the ratio of the LVM to body
surface area. Due to technical problems, 1 CRC patient
did not undergo echocardiography, and LVEF was
not measured in 4 control subjects.
A treadmill exercise test was performed according
to the Bruce or the modiﬁed Naughton protocol,
depending on the performance status of each subject.
Peak oxygen consumption (peak VO2) and anaerobic
threshold were measured as ml per kilogram body
weight per minute; the ratio of minute ventilation
and carbon dioxide output (VE/VCO2 slope) assessed
breathing efﬁciency. Absolute peak VO2 (ml/min) was
used for regression analyses. All patients exercised
until limited by symptoms and until the respiratory
exchange ratio (VCO2/VO2) was $1. One control sub-
ject, 2 CRC patients, and 4 CHF patients refused to
undergo treadmill exercise testing. One control sub-
ject, 3 CRC patients, and 11 CHF patients did not
reach a VCO2/VO2 of 1; therefore, these test results
were excluded from the analysis.
Dual-energy X-ray absorptiometry, using a Lunar
prodigy model with Lunar “enCore 2002” software
(both from GE Healthcare, Waukesha, Wisconsin)
assessed body composition. For technical reasons, 1
patient with CRC did not undergo the dual-energy
X-ray absorptiometry scanning.
All subjects underwent 24-h electrocardiographic
monitoring using a 12- or 3- channel DMS-300 recorder
(DMS, Beijing, China). The tapes were subsequently
analyzed to measure HRV using validated CardioScan
Premier 12 software (version 12.4.0051a, DMS).
NONSPECTRAL ANALYSIS. The mean RR duration
(mean of all normal intervals between 2 QRS com-
plexes) from the whole recording was assessed, and
the following measures were calculated: SD of all
normal RR intervals (SDNN), SD of 5-min mean RR
intervals (SDANN), and mean of the SD of normal RR
intervals every 5 min (SDNN index) (10).
SPECTRAL ANALYSIS. After determination of the
total oscillatory power, spectral analysis allowed
identiﬁcation of very low-frequency (VLF) (0.003 to
0.04 Hz), low-frequency (LF) (0.04 to 0.15 Hz), and
high-frequency (HF) (0.15 to 0.40Hz) components.
The power within each band was expressed in
ms2. VLF seems to be related to thermoregulation,
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1313the renin-angiotensin-aldosterone system, and pe-
ripheral vasomotor tone. LF relates to baroreﬂex ac-
tivity and is primarily inﬂuenced by sympathetic
activity. HF corresponds to the respiratory modula-
tion and is vagally mediated (10).
For technical reasons, 1 control subject, 5 CRC pa-
tients, and 2 CHF patients did not undergo electro-
cardiographic Holter monitoring. In the CHF group, 3
patients had atrial ﬁbrillation, and 19 patients had an
implanted device, such as a pacemaker (n ¼ 6), an
implanted cardioverter-deﬁbrillator (n ¼ 15), or car-
diac resynchronization therapy (n ¼ 9). Therefore,
they were excluded from this part of the analysis.
STATISTICAL ANALYSIS. Normally distributed data
are presented as mean  SD, and non-normally
distributed data are presented as median (25th and
75th percentiles). The Kolmogorov-Smirnov test
assessed normal distribution. Unpaired Student’sTABLE 3 Results of Body Composition Analysis, Treadmill Exercise T
in Control Subjects and in Patients With CRC or CHF
Characteristic
Control Subjects
(n ¼ 51)
Body composition, kg
Entire body
Lean 51.2  11.8
Fat 21.4  8.0
Arms
Lean 5.5  1.8
Fat 1.8  0.7
Legs
Lean 17.3  4.5
Fat 6.7  2.6
Cardiovascular function
Breath efﬁciency, VE/VCO2 slope 28.0 (25.0–30.0)
Anaerobic threshold, ml/kg/min 16.4  4.5
LVEDVI, ml/m2 41.4 (32.3–56.4)
LVESVI, ml/m2 16.4 (10.6–23.0)
LVMI, g/m2 84.8 (71.8–112.5)
SDNN index, ms 53.0  17.0
VLF, ms2 2173.7  1308.6
LF, ms2 691.5  430.0
HF, ms2 126.4 (83.2–246.2)
Biomarkers
MR-proADM, nmol/l 0.5  0.2
MR-proANP, pmol/l 95.2 (61.9–122.6)
CT-proET-1, pmol/l 42.7  14.6
Copeptin, pmol/l 4.1 (2.9–6.3)
hsCRP, mg/l —
hsTnT, pg/ml 5.0 (4.0–5.7)
Values are mean  SD or odds ratio (95% conﬁdence intervals). *Analysis of variance o
subjects. §p < 0.01 versus control subjects. kp < 0.05 versus patients with CHF. ¶p <
CT-proET ¼ C-terminal pro-endothelin; HF ¼ high frequency; hsCRP ¼ high-sensitivity
left ventricular end-diastolic volume index; LVESVI ¼ left ventricular end-systolic vo
adrenomedulin, MR-proANP ¼ midregional pro-atrial natriuretic peptide; SDNN index
ventilation and carbon dioxide output; VLF ¼ very low frequency.t-test, analysis of variance (ANOVA) with Fisher’s
post-hoc test, chi-square test, and simple regression
(using log-transformed data when necessary) were
used as appropriate. A p value <0.05 was considered
signiﬁcant in all experiments. Statistical analysis was
performed using StatView 5.0 (SAS Institute Inc.,
Cary, North Carolina).
RESULTS
Among the CRC patients, 47 (86%) had surgical tumor
resection, and 26 (52%) presented with metastatic
disease at the time of examination. The median time
since ﬁrst diagnosis of CRC was 22.8 months (range 2
to 24 months). Regarding tumor localization, 22 pa-
tients (44%) had adenocarcinoma of the rectum, 14
(28%) had adenocarcinoma of the sigmoid colon, 3
(6%) had adenocarcinoma of the ascending colon, 3est, Holter Electrocardiography and Biomarker Analyses
Patients With CRC
(n ¼ 50)
Patients With CHF
(n ¼ 51) p Value*
47.2  9.8† 54.3  11.0 0.005
23.8  11.1 26.2  10.3‡ 0.05
4.9  1.4† 5.9  1.4 0.007
2.2  1.1 2.4  1.1§ 0.03
15.2  3.8‡k 17.2  3.7 0.01
7.7  4.0 7.5  3.7 0.28
31.0 (28.0-34.2)§k 33.0 (29.5-38.5)¶ <0.0001
14.5  3.6‡† 11.7  3.0¶ <0.0001
46.7 (39.8–56.3)# 70.8 (49.7–97.3)¶ <0.0001
19.6 (13.4–25.6)‡# 45.5 (32.8–71.9)¶ <0.0001
87.5 (70.9-97.6)k 143.7 (113.6–175.9)§ 0.0006
41.2  13.0¶ 44.7  20.1‡ 0.003
1365.2  792.5¶ 1311.4  911.8¶ 0.0002
406.6  292.2¶ 356.7  335.0¶ <0.0001
95.7 (51.3–149.4)§ 128.4 (54.8–250.2) 0.03
0.6  0.2# 1.0  0.5¶ <0.0001
71.2 (48.4–106.2)‡# 233.2 (126.6–365.8)¶ <0.0001
55.7  22.7 — 0.005
5.7 (3.9–11.1) — 0.01
5.4 (1.8–13.4) 2.9 (1.4–4.4) 0.01
6.0 (4.0–8.2)# 17 (11–23)¶ <0.001
r chi-square p value. †p < 0.01 versus patients with CHF. ‡p < 0.05 versus control
0.001 versus control subjects. #p < 0.001 versus patients with CHF.
C-reactive protein; hsTnT¼ high-sensitivity troponin T; LF ¼ low frequency; LVEDVI ¼
lume index; LVMI ¼ left ventricular mass index; MR-proADM ¼ midregional pro-
¼ mean of the SD of normal RR intervals every 5 min; VE/VCO2 ¼ ratio of minute
TABLE 4 Results of Body Composition Analysis, Treadmill Exercise Test,
Echocardiography, Holter Electrocardiography and Biomarker Analyses in
Chemotherapy-Treated Patients and in Therapy-Naïve Patients
Control
Subjects
(n ¼ 51)
Naïve
Patients
(n ¼ 24)
Chemotherapy
Patients
(n ¼ 26) p Value*
Body composition, kg
Entire body
Lean 51.2  11.8 45.9  10.6† 48.3  9.0 0.13
Fat 21.4  8.0 24.2  10.9 23.5  11.5 0.44
Arms
Lean 5.5  1.8 4.6  1.3† 5.1  1.4 0.12
Fat 1.8  0.7 2.2  1.1 2.2  1.2 0.16
Legs
Lean 17.3  4.5 14.8  3.9† 15.9  3.5 0.05
Fat 6.7  2.6 7.7  3.5 7.8  4.7 0.29
Cardiovascular function
Peak heart rate,
min1
149.2  18.5 160.7  20.7†‡ 142.8  24.2 0.02
Peak VO2, ml/kg/min 28.0  7.0 23.4  4.3§ 20.4  5.6k <0.0001
Breath efﬁciency,
VE/VCO2 slope
28.0 (25.0–30.0) 30.0 (25.5–33.2)‡ 33.0 (30.0–38.0)k <0.0001
LVEF, % 62.5  5.7 58.9  4.5§ 59.9  5.3 0.02
SDNN index, ms 52.9  17 45.0  12.5† 37.2  12.7k 0.0003
HF, ms2 126.4 (83.2–246.2) 109.1 (84.0–161.2)‡ 68.6 (37.7–121.4)k 0.0004
Biomarkers
MR-proADM, nmol/l 0.50  0.22 0.56  0.17¶ 0.70  0.28k 0.003
MR-proANP, pmol/l 95.2 (61.9–122.6) 63.7 (41.2–89.6)§ 86.4 (51.6–115.4) 0.03
CT-proET-1, pmol/l 42.7  14.6 49.9  20.8¶ 61.1  23.5k 0.003
Copeptin, pmol/l 4.1 (2.9–6.3) 5.3 (3.5–9.2) 7.3 (4.5–11.9)§ 0.02
hsTnT, pg/ml 5.0 (4.0–5.7) 4.0 (2.0–6.5)‡ 7.0 (4.0–10.5)§ 0.007
Values are mean  SD or odds ratio (95% conﬁdence intervals). *Analysis of variance or chi-square p value.
†p < 0.05 versus control subjects. ‡p < 0.01 versus patients undergoing chemotherapy. §p < 0.01 versus
control subjects. kp < 0.001 versus control subjects. ¶p < 0.05 versus patients undergoing chemotherapy.
Peak VO2 ¼ peak oxygen consumption; other abbreviations as in Table 3.
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1314(6%) had adenocarcinoma of the transverse colon,
and 8 (16%) had adenocarcinoma in other locations.
The patients’ median carcinoembryonic antigen level
was 3.8 mg/l (1.6 to 15.2 mg/L). A total of 26 CRC pa-
tients (52%) received chemotherapy while in the
study; 21 of them (81%) received 5-ﬂuorouracil (5-FU),
2 patients received capecitabine (8%), 10 were on
irinotecan (38%), 11 received oxaliplatin (42%), 11
were on bevacizumab (42%), 1 was on cetuximab
(4%), 3 were on panitumumab (11%), and 1 was on
mitomycin (4%), according to different regimens. One
patient received radiotherapy.
There were no signiﬁcant differences in terms of
age among the 3 groups of subjects. There were no
signiﬁcant differences with regard to sex, body mass
index, and blood pressure between patients with
CRC and control subjects (Table 1). Patients with CRC
had signiﬁcantly higher heart rates at test and lower
hemoglobin values compared with patients with
CHF and control subjects (Table 1). We also foundelevated levels of hsCRP in CRC patients compared
with CHF patients (Table 1); although 50% of CRC
patients were in the normal range (hsCRP >5 mg/l,
n ¼ 25). hsTnT was signiﬁcantly increased in CHF
patients only, compared with CRC patients and
control subjects; no such elevation was noted in the
CRC patients (Table 3). Values of MR-proADM,
MR-proANP, CT-proET-1, and copeptin are given in
Tables 3 and 4. CT-proET-1 and copeptin were
signiﬁcantly increased in CRC patients compared
with control subjects. In the cancer patients, fatigue
was reported as “often” in 30%, “sometimes” in
62.5%, and “never” in 7.5%.
No statistical difference was detected between the
relatively small subgroups of CRC patients with re-
gard to sex distribution (current chemotherapy: 50%;
chemotherapy-naive: 29.2% male; p ¼ 0.13), age
(therapy group: 62.2  10.9 years; naive group: 57.3 
12.8 years; p ¼ 0.15), body mass index (therapy group:
25.5  4.9 kg/m2; naive group: 25.4  5.4 kg/m2; p ¼
0.93), heart rate (therapy group: 73.5  11.7 beats/min;
naive group: 72.3  10.2 beats/min; p ¼ 0.71), systolic
blood pressure (therapy group: 129.8  17.1 mm Hg;
naive group: 121.8  17.7 mm Hg; p ¼ 0.11), and dia-
stolic blood pressure (therapy group: 78.8  8.5
mm Hg; naive group: 74.8  8.2 mm Hg; p ¼ 0.10).
There was borderline signiﬁcance with regard to he-
moglobin levels between the 2 groups (therapy
group: 12.3  1.1 g/dl; naive group: 11.6  1.9 g/dl; p ¼
0.049). CRC patients who underwent chemotherapy
had signiﬁcantly increased values of hsCRP compared
with treatment-naive patients (therapy group: 19.5 
25.9 mg/l; naive group: 4.8  4.1 mg/l; p ¼ 0.03).
Parameters of lung function as assessed by
spirometry did not differ between patients with CRC
(forced vital capacity [FVC]: 3.5  0.9 l; forced expi-
ratory volume in 1 s [FEV1]: 2.7  0.7 l) and control
subjects (FVC: 3.9  1.0 l; p ¼ 0.12 and FEV1:
3.0  0.8 l; p ¼ 0.06), as well as between treatment-
naive patients (FVC: 3.5  0.8 l, FEV1: 2.8  0.6 l)
and those who underwent chemotherapy (FVC:
3.6  1.1 l; p ¼ 0.7, and FEV1: 2.7  0.9 l; p ¼ 0.7).
CARDIOVASCULAR CHARACTERISTICS AND BODY
COMPOSITION. Compared with control subjects,
LVEF was signiﬁcantly reduced in CRC patients and in
patients with CHF (Central Illustration). The LVESV
index was increased in both CHF and CRC patients
compared with control subjects (all p < 0.05)
(Table 3). The LVM index was signiﬁcantly increased
in patients with CHF compared with the other 2
groups (all p < 0.05) (Table 3); no such difference was
noted between patients with CRC and control sub-
jects. A thickened left ventricular posterior wall was
observed in CRC and CHF patients compared with
CENTRAL ILLUSTRATION Cardiovascular Characteristics
(A) Cardiac function as assessed by left ventricular ejection fraction (LVEF) in control subjects (blue bars), patients with colorectal cancer (CRC)
(salmon bars), and patients with chronic heart failure (CHF) (purple bars). Analysis of variance p value <0.0001. (B) Exercise capacity as
assessed by spiroergometry in control subjects (blue bars), patients with CRC (salmon bars), and patients with CHF (purple bars). Analysis of
variance p value <0.0001. (C) Heart rate variability (HRV) as assessed by SD of all normal RR intervals (darker color boxes) and SD of 5-min
mean RR intervals (lighter color boxes) in control subjects (blue bars), patients with CRC (salmon bars), and patients with CHF (purple bars).
Analysis of variance p value for SD of all normal RR intervals ¼ 0.001, for SD of 5-min mean RR intervals ¼ 0.0004.
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1315control subjects (CRC group: 10.5  1.8 mm; CHF
group: 11.0  2.6 mm; control group: 9.4  2 mm;
p ¼ 0.02 and p ¼ 0.0008, respectively). With regard to
diastolic function, no difference was observed be-
tween CRC patients and control subjects (E/A [ratio of
the peak Doppler velocities of early (E) and late dia-
stolic ﬂow (A) across the mitral valve]: CRC group: 1.0
 0.3, control group: 1.0  0.3, p ¼ 0.8; E:E0 [ratio of
the maximum velocity of early mitral valve inﬂow to
the maximal velocity of the motion of the mitral valve
at the lateral annulus]: CRC group: 8.4  2.6, control
group: 8.3  3.0; p ¼ 0.8). Patients with CHF had a
signiﬁcantly higher E:E0 (mean 12.8  6.2) compared
with the other 2 groups (both p < 0.0001). Both CRC
and CHF patients showed signiﬁcantly decreased
exercise performance as assessed by peak VO2
compared with control subjects (Central Illustration),
as well as a signiﬁcantly impaired breathing efﬁciency
and anaerobic threshold (Table 3). Although 86.6% ofcontrol subjects showed a normal peak VO2 adjusted
for age, sex, and body weight, this was the case in
44.0% of CRC patients and in 11.8% of CHF patients
(p < 0.0001). Using simple regression analysis, we
found that in CRC patients, peak VO2 correlated with
hemoglobin, lean mass (legs and entire body),
maximal heart rate on exercise, VLF, and CT-proET-1
(all p < 0.05) (Table 5). Patients with CRC who did not
receive chemotherapy showed a signiﬁcantly reduced
peak VO2 and LVEF compared with control subjects
(all p < 0.006) (Table 4).
Most parameters of HRV (e.g., SDNN, SDANN, SDNN
index, VLF, and LF) were signiﬁcantly reduced in CRC
patients and CHF patients with CRC compared with
control subjects (all p < 0.04) (Central Illustration,
Table 3). In patients with CRC, HF was also signiﬁ-
cantly decreased compared with control subjects. In
the CRC group, serum levels of hsCRP correlated with
SDNN (r ¼ 0.44, p ¼ 0.003), SDANN (r ¼ 0.40,
TABLE 5 Simple Regression Analyses (With the Respective p Value) With Peak VO2
(ml/min) Serving as the Dependent Variable in Control Subjects and in Patients
With CRC or CHF
Control Subjects
(n ¼ 51)
Patients with CRC
(n ¼ 50)
Patients with CHF
(n ¼ 51)
R p Value R p Value R p Value
Age, yrs –0.55 <0.0001 –0.19 0.20 –0.03 0.87
Body mass index, kg/m2 0.24 0.09 0.24 0.11 0.52 0.001
hsCRP, mg/l — — –0.09 0.58 –0.05 0.79
Hemoglobin, g/dl 0.29 0.045 0.36 0.01 0.26 0.13
Body composition, kg
Entire body
Lean 0.86 <0.0001 0.64 <0.0001 0.48 0.003
Fat –0.19 0.19 0.08 0.58 0.47 0.003
Legs
Lean 0.88 <0.0001 0.65 <0.0001 0.60 0.0001
Fat –0.32 0.024 –0.04 0.77 0.29 0.08
Cardiovascular function
Maximal heart rate 0.21 0.14 0.38 0.009 0.23 0.18
Breath efﬁciency, VE/VCO2 0.16 0.27 –0.46 0.001 –0.45 0.005
LVEF, % 0.002 0.99 –0.26 0.09 0.38 0.02
SDNN index, ms 0.46 0.0009 0.20 0.19 0.22 0.33
VLF, ms2 0.42 0.003 0.32 0.04 –0.12 0.59
LF, ms2 0.60 <0.0001 0.16 0.31 0.006 0.98
HF, ms2 0.35 0.01 0.09 0.56 –0.27 0.23
Biomarkers
MR-proADM, nmol/l –0.07 0.68 –0.29 0.05 0.10 0.58
MR-proANP, pmol/l –0.07 0.65 –0.26 0.09 –0.21 0.25
CT-proET-1, pmol/l –0.20 0.29 –0.30 0.04 — —
Copeptin, pmol/l 0.50 0.004 –0.22 0.15 — —
hsTnT, pg/ml 0.15 0.37 0.03 0.86 0.35 0.04
Abbreviations as in Tables 1 and 3.
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1316p ¼ 0.007), LF (r ¼ 0.33, p ¼ 0.03), and HF (r ¼ 0.41,
p ¼ 0.006). Compared with control subjects, therapy-
naive patients also had a signiﬁcantly lower SDNN
index, VLF, and LF (all p < 0.05) (Table 4). In the
treatment group, signiﬁcant correlations between
hsCRP and parameters of HRV, in particular, SDNN
(r ¼ 0.57, p ¼ 0.007), SDANN (r ¼ 0.55, p ¼ 0.009),
SDNN index (r ¼ 0.47, p ¼ 0.03), and HF (r ¼ 0.47,
p ¼ 0.04) were noted. No such relationship was
observed in the chemotherapy-naive group.
As shown in Table 3, analysis of body composition
showed a signiﬁcantly decreased lean mass in the
legs in CRC patients compared with control subjects
and those with CHF. In the subgroup of therapy-naive
patients, decreased lean mass in the arms, legs, and
entire body were observed compared with control
subjects (all p < 0.05) (Table 4). As shown in the
Online Tables 1 and 2, no material changes were
noted in our main variables of interest when CRC
patients were analyzed according to subgrouping by
local versus metastatic disease or treatment regimens
with bevacizumab versus without bevacizumab.DISCUSSION
Because this was the ﬁrst prospective study to sys-
tematically examine parameters of cardiovascular
function in CRC patients, our data demonstrated that
CRC patients’ exercise capacity is severely impaired
compared with their age-matched control subjects. In
addition, we found that a mild, but statistically sig-
niﬁcant, reduction of the LVEF in CRC patients was
present, and that all markers of HRV were decreased
in these patients. Although the reduction in LVEF
appeared to be similar in patients with or without
chemotherapy, the reduction in HRV not only
reached the level of that in patients with CHF, but it
was further reduced by commencement of chemo-
therapy, a therapeutic step that also led to increases
in hsTnT values. This effect was underscored by the
lower peak heart rate and lower peak VO2 during
exercise after chemotherapy initiation. Although
serum levels of MR-proADM and MR-proANP were
similar in patients with CRC and controls subjects,
and never reached those of patients with CHF, levels
of CT-proET-1 and copeptin were elevated in CRC
patients compared with control subjects.
Exercise testing using spiroergometry, and thus
peak VO2 measurement, is viewed as an objective
measure of cardiopulmonary exercise capacity. Al-
though not reduced to the level of CHF patients, ex-
ercise capacity of CRC patients is severely impaired
compared with control subjects, and this effect is
independent of chemotherapy. Several of our ﬁnd-
ings suggested themselves as explanations for these
ﬁndings: the mild reduction in LVEF, the severe
reduction in HRV, the reduction in lean mass in
the legs, the reduction in hemoglobin, inﬂammatory
activation, and the progressive endothelial dysfunc-
tion, as reﬂected by elevated levels of CT-proET-1.
These effects might also help in understanding the
impaired exercise capacity in other clinical entities,
such as coronary artery disease (11), CHF with digoxin
therapy (12), in elderly patients (13,14), and in pa-
tients after heart transplantation (15). These patients
present with limited exercise capacity. The assess-
ment of HRV using standard 24-h measurements
could also help to understand sympathetic and
parasympathetic activity levels. In CRC patients,
sympathetic function and parasympathetic function
seemed to be decreased to a similar extent. Interest-
ingly, the reduction in parasympathetic tone, as re-
ﬂected by HF analysis, is more pronounced in CRC
than in CHF, whereas sympathetic tone, reﬂected
by LF analysis, is more severely reduced in CHF
than in CRC. However, these effects may be easily
explained by the use of beta-blockers in patients
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1317with CHF. Studies in patients with essential hyper-
tension, post-infarction patients, and in CHF patients
have conﬁrmed that beta-blockers decrease sympa-
thetic ﬂuctuations and increase parasympathetic
ﬂuctuations, and thus, are able to restore the sym-
pathetic–parasympathetic balance in cardiovascular
disease (16). Interestingly, in our study, the subgroup
of chemotherapy-treated patients had a signiﬁcantly
lower HF component compared with therapy-naive
patients. The HF corresponded to short-term
changes in the heart rate and was an indicator
of parasympathetic performance. In therapy-naive
patients, HF was in the normal range, similar to
control subjects (p ¼ 0.35), indicating that impair-
ment of the parasympathetic system occurs in the
early stages of therapy. Impairment in sympathetic
activity does not seem to be inﬂuenced by chemo-
therapy, because the LF component was reduced to
the same extent in the 2 groups. In line with reduced
HRV, patients who underwent chemotherapy had a
decreased maximal heart rate during exercise testing
compared with that of therapy-naive patients. Our
study was not designed to provide direct insight into
the mechanisms involved in these perturbations;
however, the much higher levels of hsCRP in treated
patients and the associations between hsCRP and
HRV in this group buttressed the view that activation
of inﬂammatory pathways were involved.
In accordance with numerous previous reports, our
study revealed overactivity of hsCRP in cancer pa-
tients (17,18). Such effects might have secondary
consequences on endothelial function, as underlined
by increased levels of CT-proET-1, which is a potent
vasoconstrictor peptide secreted mainly by endothe-
lial cells (19,20). Therefore, the overactivity of hsCRP
might also serve as a proxy for endothelial function
(21); these effects were directly associated with ex-
ercise capacity in the CRC patients.
Although we found that many parameters of car-
diovascular function were impaired in CRC patients,
whether or not they were currently treated with
chemotherapy, it was reassuring to note that the
echocardiographic parameters were hardly affected.
In addition, although they did not fulﬁll the criteria of
tachycardia, the CRC patients in our study demon-
strated signiﬁcantly higher heart rates at rest than the
patients with CHF or the control subjects. It was al-
ready demonstrated that with normal left ventricular
systolic function, the ﬁrst sign of cardiac damage
might be tachycardia (22). In our study, we observed
more prominent cardiac alterations in patients after
commencement of chemotherapy, which aligned with
the ﬁndings in previous reports. 5-FU is the key drug
for chemotherapy of CRC. Cardiotoxicity, which hasbeen recognized in other anticancer agents, has also
been reported after 5-FU administration (23), mostly
as ischemic cardiomyopathy, but also as cardiac fail-
ure (24). Another study showed a reversible and
asymptomatic decrease in left ventricular systolic
function in patients who received 5-FU; an impair-
ment of diastolic function was also observed (25).
From a clinical standpoint, our ﬁndings might help
in understanding the impaired exercise capacity of
CRC patients. Both CRC and CHF patients are affected
by systemic inﬂammation and endothelial dysfunc-
tion. Unlike CHF patients, CRC patients only present
with mildly reduced LVEF, whereas reduced exercise
capacity and reduced HRV are present in both clinical
entities. From a symptomatic standpoint, it might be
possible to understand some of the symptomatic
similarities between the 2 syndromes. Inﬂammatory
pathways might be involved in the onset of clinical
symptoms.
There is ample evidence that inﬂammation is asso-
ciated with a number of pathophysiological changes
and co-morbidities in patients with CHF, for example,
muscle wasting (26) and generally poor outcomes (27).
Likewise, the relationship between inﬂammatory
markers and fatigue already has been shown in many
studies in advanced cancer patients (28,29). However,
the most important clinical determinant of quality of
life is the exercise capacity of patients (30–32). HRV
also seems to be an important clinical determinant for
quality of life. Patients’ heart rates appear to be “stiff”
and unable to adjust to the requirements of the activ-
ities of daily living. Decreased HRV has been shown to
worsen multiple clinical symptoms, such as fatigue,
nausea, erectile dysfunction, constipation, increased
proinﬂammatory cytokines, and increased risk of
sudden death (33–35).
STUDY LIMITATIONS. Although we consider the
number of patients in the present study adequate,
larger studies should conﬁrm our ﬁndings.
CONCLUSIONS
In total, our data showed that exercise capacity
in patients with CRC was signiﬁcantly reduced. This
ﬁnding was already true in patients before com-
mencement of chemotherapy and was worsened
further by this therapy. The reduction in LVEF, HRV,
lean mass in the legs, and reduction in hemoglobin, as
well as inﬂammatory activation and progressive
endothelial dysfunction all appeared to play a role in
this regard. Our data suggested that treatments that
tackle these phenomena might have beneﬁcial ef-
fects. Such treatments include exercise programs
(36,37) and drug classes, such as beta-blockers (38–43)
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Patients with CRC often display dyspnea and fatigue
due to impaired cardiovascular function independent
of chemotherapy.
TRANSLATIONAL OUTLOOK: The efﬁcacy of
beta-blockers and angiotensin-converting enzyme
inhibitors in conjunction with regular exercise in
improving dyspnea and cardiovascular function in
patients with CRC should be evaluated in future
studies.
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All of these have positive effects on HRV and endo-
thelial function. Additional studies are required to
verify such effects.
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